Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends RA drug

The UK's National Institute for Health and Clinical Excellence has issued final guidance recommending Centocor Ortho Biotech's rheumatoid arthritis drug Simponi in specific, limited circumstances

The UK's National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending Centocor Ortho Biotech's rheumatoid arthritis (RA) drug Simponi (golimumab) for use on the NHS in specific, limited circumstances.

The drug is recommended for adults with severe active RA used in combination with methotrexate in cases where 'conventional' disease-modifying antirheumatic drugs (DMARDs) have been ineffective.

It is also recommended for similar patients who have tried other types of DMARDs, including a tumour necrosis factor (TNF) inhibitor, but these treatments have also been ineffective and the patient is unable to take rituximab therapy for medical reasons or because of a previous bad reaction.

Dr Carole Longson, Health Technology Evaluation Centre director at NICE said: "This final guidance sets out the circumstances where golimumab can now be offered by the NHS as a treatment option for people with rheumatoid arthritis for whom previous treatments have not worked.

"Rheumatoid arthritis treatments help to relieve pain, improve mobility and reduce the long-term damage often experienced by people with this condition."

22nd June 2011

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....